文献速递区域麻醉与超声疼痛医学

连续后路胸外筋膜平面阻滞与连续椎旁阻滞用于多发肋骨骨折镇痛的非劣效随机对照试验

Continuous posterior extrathoracic fascial plane block versus continuous paravertebral block for pain management in patients with multiple rib fractures: a randomised controlled noninferiority trial.
PubMed 文献 · Br J Anaesth · 2025-11-20

本研究为随机对照非劣效试验,纳入90例非机械通气的多发肋骨骨折创伤患者,比较连续后路胸外筋膜平面阻滞(PEFB)、连续椎旁阻滞(PVB)与全身镇痛对24小时吗啡消耗量等指标的影响。结果显示PEFB组24小时吗啡消耗量非劣效于PVB组,但PEFB组更多患者需要胸段硬膜外镇痛补救,且PVB组在咳嗽时疼痛缓解和呼吸参数改善更优。

要点

  • PEFB在24小时吗啡消耗量上非劣效于PVB(17 mg vs 22 mg,P<0.001)。
  • PEFB组30%需胸段硬膜外补救,高于PVB组的6.7%(P=0.043)。
  • PVB组咳嗽时疼痛评分更低(交互β=-0.58,P=0.010),最大呼气压更高。

核心结论

  • 在多发肋骨骨折患者中,PEFB对24小时吗啡消耗量的效果非劣效于PVB。
  • PEFB可作为肋骨骨折镇痛的一线选择,但比PVB更可能需要胸段硬膜外麻醉补救。
  • PVB组在咳嗽时疼痛缓解和呼吸参数改善方面更优。

研究设计与样本

  • 随机对照非劣效试验,纳入90例非机械通气的多发肋骨骨折创伤患者,随机分为PEFB、PVB和全身镇痛三组。
  • 主要终点为24小时吗啡消耗量;次要终点包括静息和咳嗽时疼痛、72小时吗啡消耗量、胸段硬膜外镇痛补救、SNIP和MEP,采用线性混合模型分析。

主要发现

  • PEFB组24小时吗啡消耗量为17(11-29)mg,PVB组为22(14-31)mg,P<0.001(非劣效)。
  • 对照组和PEFB组各有30%患者、PVB组6.7%患者在研究期间接受胸段硬膜外镇痛(P=0.043)。
  • 符合方案分析中,72小时吗啡消耗量对照组为45(36-72)mg,PEFB组30(16-44)mg,PVB组38(22-62)mg(P=0.051)。
  • 所有组咳嗽时疼痛评分均更高(β=3.89,P<0.0001),但PVB组有显著交互作用且评分更低(β=-0.58,P=0.010)。
  • 72小时内所有组SNIP值较基线显著增加(β从7.2到14.9;P=0.002),PVB组MEP值更高(β=12.71,95%CI 2.73-22.77;P=0.012)。

临床怎么用

  • PEFB可作为多发肋骨骨折镇痛的一线区域阻滞选择,但需警惕可能需要胸段硬膜外镇痛补救。
  • 若更关注咳嗽时疼痛缓解和呼吸功能改善,PVB可能优于PEFB。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pain control is key to the management of patients with multiple rib fractures. We compared the impact of posterior extrathoracic fascial plane block (PEFB) with paravertebral block (PVB) and systemic analgesia on morphine consumption, pain relief, and improvement in respiratory parameters. METHODS: Trauma patients with multiple rib fractures who were not mechanically ventilated were randomised into three groups: PEFB, PVB, and systemic analgesia. The primary endpoint was morphine consumption at 24 h. The secondary endpoints (pain at rest and when coughing, morphine consumption in the first 72 h, rescue thoracic epidural analgesia, sniff nasal inspiratory pressure [SNIP], and maximal expiratory pressure [MEP]) were analysed using linear mixed models. RESULTS: Of the 90 patients included in the study, 77.7% were male; median (interquartile range) Injury Severity Score was 14 (10-19), chest Abbreviated Injury Scale was 3 (3-4), and number of ribs fractured was 4.5 (5-9). Morphine consumption at 24 h in the PEFB group was noninferior to that in the PVB group (17 [11-29] mg and 22 [14-31] mg, respectively; P<0.001). Thirty percent of patients in the control and PEFB groups and 6.7% in the PVB group (P=0.043) had thoracic epidural analgesia during the study. In the per-protocol analysis, morphine consumption at 72 h was higher in the control group but with no significant difference between intervention groups: control, 45 (36-72) mg; PEFB, 30 (16-44) mg; and PVB, 38 (22-62) mg (P=0.051). Pain scores were higher during coughing in all groups (β=3.89, P<0.0001), but scores were lower with a significant interaction in the PVB group (β=-0.58, P=0.010). Over 72 h, SNIP values increased significantly from baseline (β from 7.2 to 14.9; P=0.002) in all groups, and MEP values showed a difference with higher values in the PVB group (β=12.71, 95% confidence interval 2.73-22.77; P=0.012). CONCLUSIONS: Posterior extrathroacic fascial plane block promoted a noninferior effect on morphine consumption at 24 h compared with paravertebral block in patients with multiple rib fractures. However, although PEFB has merit as a first-line treatment for rib fracture analgesia, it is more likely than PVB to require thoracic epidural anaesthesia rescue. Pain relief during coughing and respiratory parameters improved more in the PVB group. CLINICAL TRIAL REGISTRATION: NCT03396692.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Ramin S, Charbit J, Airoldi F, et al. Continuous posterior extrathoracic fascial plane block versus continuous paravertebral block for pain management in patients with multiple rib fractures: a randomised controlled noninferiority trial. Br J Anaesth. 2025. PMID: 41271472. doi:10.1016/j.bja.2025.09.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。